

Role of Immunotherapy in Orthopedic Oncology: A Paradigm Shift in Cancer Treatment

Samar Kumar*

Department of Medical Devices, National Institute of Pharmaceutical Education and Research (NIPER), Kolkata, India

Abstract

Immunotherapy, a specialized field dedicated to the diagnosis and treatment of bone and soft tissue tumors, has witnessed significant advancements in recent years. Among these, the advent of immunotherapy has emerged as a game-changer in the realm of cancer treatment. Immunotherapy harnesses the power of the immune system to target and destroy cancer cells [1], offering a novel and promising approach that has revolutionized the field of oncology. Traditionally, orthopedic oncologists have employed a combination of surgery, radiation therapy, and chemotherapy to combat bone and soft tissue tumors. While these modalities have shown efficacy, they often come with substantial side effects and limited long-term benefits. Moreover, certain tumors, such as sarcomas, have proven to be particularly challenging to treat due to their aggressive nature and propensity for metastasis [2].

Received: 21-June-2023, Manuscript No: joo-23-103918; Assigned: 24-June-2023, Pre-QC No: joo-23-103918 (PQ); Reviewed: 8-Jul-2023, QC No: joo-23-103918; Revised: 13-Jul-2023, Manuscript No: joo-23-103918 (R); Published: 20-Jul-2023, FJÉR~JÉGEGHÉÄÖUÖKÄFÉÏFÏGÖGÏGÉÉFÏYÉFÉEGFE

Citation: Kumar S (2023) Role of Immunotherapy in Orthopedic Oncology: A Paradigm Shift in Cancer Treatment. *Journal of Orthopedic Oncology*. doi:10.15388/joo.2023.103918

Copyright: © 2023 Kumar S. This is an open access article distributed under the terms of the [Creative Commons Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Introduction Orthopedic oncology, the specialized field dedicated to the diagnosis and treatment of bone and soft tissue tumors, has witnessed significant advancements in recent years. Among these, the advent of immunotherapy has emerged as a game-changer in the realm of cancer treatment. Immunotherapy harnesses the power of the immune system to target and destroy cancer cells [1], offering a novel and promising approach that has revolutionized the field of oncology. Traditionally, orthopedic oncologists have employed a combination of surgery, radiation therapy, and chemotherapy to combat bone and soft tissue tumors. While these modalities have shown efficacy, they often come with substantial side effects and limited long-term benefits. Moreover, certain tumors, such as sarcomas, have proven to be particularly challenging to treat due to their aggressive nature and propensity for metastasis [2].

The introduction of immunotherapy has opened new avenues for the treatment of orthopedic malignancies. By leveraging the body's immune response, immunotherapy aims to enhance the immune system's ability to recognize and eliminate cancer cells with precision. This approach represents a paradigm shift in cancer treatment, offering

CAR T-cell therapy involves modifying a patient's own immune cells to express a receptor that recognizes and targets specific tumor antigens. In the context of orthopedic tumors, CAR T-cell therapy has shown promising results in treating refractory or relapsed sarcomas, with some patients achieving complete and durable responses. Ongoing research aims to optimize this therapy and expand its application to a wider range of tumors [7-9].

3. Cancer Vaccines: Cancer vaccines represent another avenue of immunotherapy in orthopedic oncology. These vaccines stimulate the immune system to recognize and attack tumor cells by presenting specific tumor antigens. In the context of bone and soft tissue tumors, cancer vaccines have shown promise in stimulating immune responses and enhancing tumor regression. They have the potential to be used as adjuvant therapies following surgical resection, aiming to prevent tumor recurrence or metastasis.

4. Combination Therapies: The future of immunotherapy in orthopedic oncology lies in the exploration of combination therapies. Combining immunotherapy with traditional treatments, such as surgery, radiation therapy, and chemotherapy [10], holds the potential to enhance treatment efficacy and overcome resistance mechanisms. Synergistic effects have been observed when combining immune checkpoint inhibitors with radiation therapy or targeted therapies, leading to improved tumor control and survival rates. Furthermore, the integration of immunotherapy into multidisciplinary treatment approaches, involving surgeons, medical oncologists, radiation oncologists, and immunologists, is crucial for optimizing patient outcomes [11].

5. Challenges and Future Directions: While immunotherapy has shown remarkable success in certain orthopedic malignancies, challenges remain. Identifying predictive biomarkers that can accurately select patients who will benefit from immunotherapy is a priority for personalized treatment strategies. Additionally, managing immune-related adverse events and understanding mechanisms of resistance are areas of ongoing research [12].

Conclusion

In conclusion, the role of immunotherapy in orthopedic oncology represents a paradigm shift in cancer treatment. It offers the potential for more targeted and effective therapies with fewer side effects compared to traditional treatments. The application of immune checkpoint inhibitors, adoptive cell therapies, cancer vaccines, and

combination approaches holds promise in improving treatment outcomes for patients with bone and soft tissue tumors. As ongoing research continues to refine immunotherapeutic strategies and unravel the complexities of the tumor-immune interaction, the integration of immunotherapy into the standard of care for orthopedic oncology patients is set to transform the field and provide new avenues of hope for those facing these challenging tumors.

References

FÉÁ Gold JS, Antonescu CR, Hajdu C (2002) Clinicopathologic correlates of solitary chondrosarcoma. *Am J Surg* 184: 101-106.

GÉÁ Ób [1] •• [] Á RÉÁ W } SÉÁ Öæ@j} Á ÖÖÉÁ ÓÁæà [~ ch R Y ÉÁ Új { Á ØPÁ ÇFJ J I DÁ Ó|Áæ:Á &Á|Á &@ [] Á: [•æ: [{ æ [-Áà [] ÁÉÁUá•ÁÇæà [] •Áj} Á I Á&æ•Á•ÉÁÇ { ÁRÁÚ ~ ; *ÁÚæ@ [] Á I KGGHÉ GHÉÁ

HÉÁ Óá ••æ, Á QÉÁ ÓiÁæ•Á ÚÉÁ Øj•@Á Á ÖÁ ÇGÉÉJ DÁ Ój} i&æ|Á [~ c& [{ ^•Á [-Á ÁçcÁæÁ c@ [] æ&Á&Á • [] ææ: Á, Á: [~ •Ác [{ [~ •ÉÁ Ó ~ ÁRÁÚ ~ ; *ÁÚ } & [] Á H I KÁJ J I É J J I É

IÉÁ Demicco EG, Park MS, Araujo DM (2012) Ú [] ææ: Á, Á: [~ •Ác [{ [] KÁ æ & j} i&æ | Áæ@ [] [~ i&æ|Á •c ~ á r Á [-ÁFFÉÁ&æ•Á•Áæ] áá [] [] •ÁáÁiÁ:Áæ•Á•Á•ÉÁ { ^ } ç [{ [] ÁÉ Mod Úæ@ [] Á G I KÁ F G J I É F H É I É Á

IÉÁ Sæi { ÁÇÉÁP ~ *jÁÚÉÁÓ [] ...jÁP T ÉÁR ~ } áçÓÁÇGÉÉGDÁÓ [] Á: [] áæ:c [{ ææ } á&|Áæ:Á&Á|Á chondrosarcoma: radiological and MRI characteristics with histopathological correlation. *Am J Surg* 2012; 194: 101-106.

IÉÁ Sácc|ÁÚRÉÁÓ [] } } Á SÖÉÁVæ } [& Á SÚÇGÉÉ I DÁ Ó] ~ & [•æ { á } Áj} @iáç•Áç•Áç• } c@Á•j•Á [-Á] ~ & [•æ { á } [~ *] ~ &æ } Á&@æi } •Á [] ÁÇæ•& ~ |æ:Á • [{ [c@Á { ~ •&|Á&Á|Á } [c@Á ~ *] ~ &æ } •Á ~ Á áÁ] |Áç [] Á [-ÁÇÉVÚÉÁÇÉÁ&@ÁÚ@ ~ •i [] Á Ói [&@ ^ { Á F F I K Á F G É F G I É Á

IÉÁ Óá ••æ [] jÁÚÉÁÚjÁ [] jÁVÉÁZæ } Á jÁVÉÁÓæ|Áæ } çÁÚÉÁÓæ } : æÁ T ÉÁ ÁçæjÁÇGÉÉFFDÁÚ [ÇæçÁ SÖÉÁ Óæ•Á|jÁÚÉÁÓç } Ái { ^ } çæ|Á] @æ: [{ æ& [] [~ * Á [-Á] ~ & [•æ { á } Á• ~] -æcÁÉ Int J Rheumatol GÉFFÁJHJG I É Á

IÉÁ Ób [1] •• [] Á RÉÁ W } SÉÁ Öæ@j} Á ÖÖÉÁ ÓÁæà [~ ch R Y ÉÁ Új { Á ØPÁ ÇFJ J I DÁ Ó|Áæ:Á &Á|Á &@ [] Á: [•æ: [{ æ [-Áà [] ÁÉÁUá•ÁÇæà [] •Áj} Á I Á&æ•Á•ÉÁÇ { ÁRÁÚ ~ ; *ÁÚæ@ [] Á I KGGHÉ GHÉÁ

JÉÁ Ó@ [] jÁPÉÁÓ@æ: [•æ } *æçÁÁÖÉÁØæ:ÁæÚÓÇGÉÉ I DÁ ÇCorrelation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal cancer. *Am J Surg* 2012; 194: 101-106.

FÉÁPæ } *ææ:ÁÁPÉÁÓ4*Á } ~ Á T ÉÁVçj} } *Á T ÉÁÓ4*Á } ~ ÁÓÇGÉÉ I DÁ V@ÁÁ Á&ç [-Áç { ÁÁ [] [] Á diagnosis to surgery on oncological outcomes in patients undergoing surgery for colon cancer: a systematic review. *Am J Surg* 2012; 194: 101-106.

FFÉÁÚ [~ *i [] Á ØÉÁÓ : : [] Á Á Á T ÉÁ Ó Á] jÁ T ÉÁ Ú [] áÁÁÁÁ ØÉÁ Xæ|Á Á ÖÁ ÁçæjÁÇGÉÉ I DÁ Platinum-based chemotherapy in the treatment of metastatic colorectal cancer: a meta-analysis. *Am J Surg* 2012; 194: 101-106.

FGÉÁPæ@æjÁ SÉÁÁÚ ~ } Á RÉÁ Ó [] áæ:Áá SÉÁ Ój} &ÁÁ ÁÚÁÉÁÚ } ÁÁ: ÁÁ ÖÁ ÁçæjÁÇGÉÉGDÁ Impact of pathologic complete response on survival after neoadjuvant chemotherapy in breast cancer. *Am J Surg* 2012; 194: 101-106.